Clinical trials: Malignant Pleural Effusion
Pleural Effusion, Pleural Effusion, Malignant
Multiple Biomarkers in Undiagnosed Pleural Effusion
The purpose of this clinical trial is to evaluate the ability of various biomarkers measured in serum and/or pleural fluids to estimate the risk of finding cancer in patients with undiagnosed pleural effusions.
- Trial name
- NCT00316134
- Testing
- Procedure/Surgery
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Fujirebio Diagnostics, Inc.
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumors, Malignant Pleural Effusions
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in…
- Conditions
- Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
- Trial name
- NCT07615894
- Testing
- WSK-IM02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Lung Cancer, Small Cell Lung Cancer
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
This trial is titled "A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC)." Part 1, the phase 1b portion of this study, is a…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- SCLC (NCT00791154)
- Testing
- AMG 479, Etoposide, AMG 102
- Volunteers
- 213 people
- Sponsor
- NantCell, Inc.
Malignant Pleural Effusion
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
To evaluate the safety and tolerability of single dose of SCB-313 by intrapleural injection.To evaluate the safety and tolerability of repeated dose of SCB-313 by intrapleural injection once a day for 3 days, and to determine the…
- Trial name
- NCT04123886
- Testing
- SCB-313
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Pleural Effusion, Pleural Effusion, Malignant
Use of Guidance Videos to Increase Engagement and Decrease Anxiety in Patients Undergoing Pleural Tap
Patients planned to undergo a pleural tap will get verbal explanation or watch a personalized guidance video in addition to verbal explanation.
- Conditions
- Pleural Effusion, Pleural Effusion, Malignant, Pleural Pleurisy Effusion
- Trial name
- NCT04254445
- Testing
- Personalized training video
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- GistMed Ltd.
Malignant Pleural Effusion
Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients
Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion
- Trial name
- NCT02191540
- Testing
- Abnoba Viscum F 20mg
- Where
- 3 sites in South Korea
- Volunteers
- 68 people
- Sponsor
- Abnoba Korea
Malignant Pleural Effusions
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via intrapleural injection (SAD) and once daily over…
- Trial name
- NCT03869697
- Testing
- SCB-313
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Malignant Pleural Effusions (Mpe)
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
- Trial name
- NCT06740019
- Testing
- JMKX000197, Tube thoracostomy drainage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jemincare
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Malignant Pleural Effusion
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
Malignant Pleural Effusion or Ascites is a common complication of malignant tumor, The objective of this study is to compare the efficacy of Endostar/cisplatin with placebo/cisplatin in patients with malignant pleural effusion or…
- Trial name
- NCT04914598
- Testing
- ENDOSTAR，cisplatin
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Malignant Solid Tumor, Malignant Pleural Effusion
A Study of MT027 in Patients with Pleural Malignant Tumors
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who…
- Conditions
- Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma
- Trial name
- NCT06726564
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Pleural Effusion
The ACES Study for Aseptic Pleural Effusion
The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid.
- Trial name
- NCT06210685
- Testing
- Automatic Continuous Effusion Shunt implantation
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Pleural Dynamics, Inc.
Malignant Pleural Effusion, Malignant Ascites
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.
- Trial name
- NCT01327235
- Testing
- Endostar, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Malignant Pleural Effusion
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
- Trial name
- NCT05923515
- Testing
- JMKX000197
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Jemincare
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Non-small Cell Lung Cancer Registry
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has…
- Trial name
- NCT00099541
- Testing
- zoledronic acid
- Where
- 101 sites in United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Pleural Effusion
Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion
Objective of this study is to investigate of efficacy and safety of recombinant adenoviral human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin.
- Trial name
- NCT02429726
- Testing
- rAdp53, Cisplatin, rAdp53 plus cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi
Lung Cancer
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00431015
- Testing
- IPI-504
- Where
- 11 sites in United States
- Volunteers
- 88 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Malignant Pleural Effusions
A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions
The purpose of this study is to determine whether a new catheter is safe and effective in treating malignant pleural effusions.
- Trial name
- NCT02227732
- Testing
- New Indwelling Pleural Catheter
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- C. R. Bard